News for VYNE Stock

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update VYNE Therapeutics Provides Update on VYN202 Program VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update VYNE Therapeutics to Participate in March Investor Conferences VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor VYNE Therapeutics to Participate in September Investor Conferences VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 VYNE Reports First Quarter 2024 Financial Results and Provides Business Update VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors VYNE Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update VYNE Therapeutics to Host Virtual R&D Day Event on November 9, 2023 VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202 VYNE Therapeutics Announces Private Placement of $88 Million VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo VYNE Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference VYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update VYNE Therapeutics to Attend BIO International Convention VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update VYNE Therapeutics Announces Selection of Development Candidate VYN202, a Potential Best-in-Class Oral Small Molecule BD2-Selective BET Inhibitor for the Treatment of Immuno-Inflammatory Conditions VYNE Therapeutics Announces Positive Preclinical Data for Inhaled Formulation of VYN201 in an In Vivo Model of Idiopathic Pulmonary Fibrosis VYNE Therapeutics Announces Positive First-In-Human Pharmacokinetic and Hematology Data from Phase 1a Single and Multiple Ascending Dose Trial for Novel Pan-Bromodomain BET Inhibitor VYN201 VYNE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammation Disease Virtual Conference VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule VYNE Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201 VYNE Therapeutics Announces Reverse Stock Split VYNE Therapeutics Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201 VYNE Therapeutics to Participate in the LifeSci Partners 12th Annual Corporate Access Event VYNE Therapeutics Announces First Patent Granted for Novel BET Inhibitor Platform VYNE Therapeutics to Participate in Cantor Fitzgerald’s Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference VYNE Therapeutics Reports Second Quarter 2022 Financial Results VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform VYNE Therapeutics to Present at LifeSci Partners’ Immunology & Inflammation Symposium on May 10th VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo VYNE Therapeutics to Present at 42nd Annual Cowen Healthcare Conference VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis VYNE Therapeutics Divests Topical Minocycline Assets VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access Event VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass and Overall Skin Repair Outcomes in Preclinical Study VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021 Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical Studies VYNE Therapeutics Announces Formation of Scientific Advisory Board VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021 VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021 VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis VYNE Therapeutics to Report Financial Results for the Year Ended December 31, 2020 on March 4 VYNE Therapeutics Announces Reverse Stock Split VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company VYNE Therapeutics to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event this Week VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne VYNE Therapeutics Added to Nasdaq Biotechnology Index VYNE Therapeutics Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (minocycline) topical foam, 4% VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology VYNE Therapeutics to Present at the 32nd Annual Piper Sandler Healthcare Conference VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st